# Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

> **NCT03176472** · PHASE2 · COMPLETED · sponsor: **Regenacy Pharmaceuticals LLC** · enrollment: 282 (actual)

## Conditions studied

- Painful Diabetic Peripheral Neuropathy

## Interventions

- **DRUG:** ricolinostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03176472
- **Lead sponsor:** Regenacy Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-07
- **Primary completion:** 2022-10-31
- **Final completion:** 2023-04-28
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03176472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03176472, "Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03176472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*